skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Jared Wolff, Zach McLellan, Kevin Shannon and Jack Allen discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast. 



Topics covered in this episode include:


- Kite Therapeutics (KITE) axicabtagene ciloleucel development update - 0:34
- Review of recent data from oral statin add-on therapies bempedoic acid (ESPR) and gemcabene (GEMP)- 4:47
- Fibrogren (FGEN) and Galapagos (GLPG) data readouts in idiopathic pulmonary fibrosis - 12:01
- PARP second quarter earnings review (AZN, TSRO, CLVS, PFE)- 16:50


Click here to listen





Click here to learn more about Datamonitor Healthcare and our offerings


  • Datamonitor Healthcare: 医療用医薬品の市場調査レポート



    Topics Coronavirus Vaccines

  • Datamonitor Healthcare: 医療用医薬品の市場調査レポート, Biomedtracker: 開発中医...


    By Dustin Phan


    Topics Coronavirus Clinical Trials

  • Datamonitor Healthcare: 医療用医薬品の市場調査レポート

    mHealth and Research in Oncology

    The World Health Organization defines mobile health (mHealth) as a “medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices”. In the last decade, the health sector has seen a substantial rise in the number of mHealth apps, many of which are designed to assist users in weight reduction and diabetes management. In 2016, there were 79,000 apps available in the Health & Fitness category in the Google and Apple stores. However, the implementation of mHealth in oncology is lagging, and there are comparatively few available apps. There is a need for the development of more mHealth apps in oncology settings considering the increasing disease burden and potential clinical benefit.